Accelerating clinical trials and access to treatments by Lawrence Korngut, MD, and Blaine Penny, Calgary, Canada This is a very exciting time for the FSHD community, as new therapeutics are… Read More »
The Global FSHD Innovation Hub
Getting treatments to young patients
MOVE Peds is essential to pave the way by Natalie Katz, MD, and Katy de Valle, research physical therapist More than 50% of people with FSHD develop symptoms as children… Read More »
XPRIZE for FSHD research
SOLVE FSHD, a venture philanthropic organization established to catalyze innovation in Facioscapulohumeral muscular dystrophy (FSHD) research, is partnering with the nonprofit organization XPRIZE Foundation to host a global competition to… Read More »
FDA Patient Listening Session
Upper body mobility: A crucial focus in FSHD treatment by Anna Gilmore, FSHD Society On August 23, 2024, the FSHD Society brought a fresh perspective to the Food and Drug… Read More »
Avidity begins Cohort C enrollment in FORTITUDE trial
Avidity begins Cohort C enrollment in FORTITUDE trial Avidity Biosciences has begun enrollment of Cohort C of the Phase 1/2 FORTITUDE™ clinical trial. Below is Avidity’s letter to the FSHD… Read More »